| n (%) or median (IQR) | P-value | |||
---|---|---|---|---|---|
Severe/Critically ill | Â | ||||
Category | Clinical management and outcome | Yes (N = 64) | No (N = 561) | All (N = 625) | |
Supportive treatments | Inotropic and vasoconstrictive agents | 5(7.8%) | 0(0.0%) | 5(0.8%) | <.0001 |
Nasal cannula | 53(82.8%) | 168(29.9%) | 221(35.4%) | <.0001 | |
Mask | 12(18.8%) | 2(0.4%) | 14(2.2%) | <.0001 | |
High-flow nasal cannula oxygen therapy | 24(37.5%) | 1(0.2%) | 25(4.0%) | <.0001 | |
Non-invasive ventilation | 34(53.1%) | 0(0.0%) | 34(5.4%) | <.0001 | |
Intermittent mandatory ventilation | 5(7.8%) | 0(0.0%) | 5(0.8%) | <.0001 | |
Prone position | 17(26.6%) | 1(0.2%) | 18(2.9%) | <.0001 | |
Continuous renal replacement therapy | 1(1.6%) | 0(0.0%) | 1(0.2%) | 0.1024 | |
Extracorporeal membrane oxygenation | 2(3.1%) | 0(0.0%) | 2(0.3%) | 0.0103 | |
Lung transplantation | 2(3.1%) | 0(0.0%) | 2(0.3%) | 0.0103 | |
Medical drugs | Traditional Chinese medicine | 29(45.3%) | 69(12.3%) | 98(15.7%) | <.0001 |
Immunoglobulin | 50(78.1%) | 106(18.9%) | 156(25.0%) | <.0001 | |
Interferon | 47(73.4%) | 456(81.3%) | 503(80.5%) | 0.1363 | |
Antioxidants | 35(54.7%) | 117(20.9%) | 152(24.3%) | <.0001 | |
Glucocorticoid | 52(81.3%) | 90(16.0%) | 142(22.7%) | <.0001 | |
Thymosin | 43(67.2%) | 101(18.0%) | 144(23.0%) | <.0001 | |
Neurotrophic drugs | 21(32.8%) | 81(14.4%) | 102(16.3%) | 0.0005 | |
Any antibiotics | 59(92.2%) | 277(49.4%) | 336(53.8%) | <.0001 | |
Any antivirals | 64(100%) | 516(92.0%) | 580(92.8%) | 0.0098 | |
Clinical outcome | Death | 0(0.0%) | 0(0.0%) | 0(0.0%) | NC |
Hospital stay | 21.5(15.0–29.0) | 15.0(12.0–21.0) | 16.0(12.0–22.0) | <.0001 |